AlphaQuest LLC Takes $285,000 Position in Omeros Co. (NASDAQ:OMER)

AlphaQuest LLC acquired a new position in shares of Omeros Co. (NASDAQ:OMER) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 28,894 shares of the biopharmaceutical company’s stock, valued at approximately $285,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in OMER. US Bancorp DE bought a new stake in Omeros during the fourth quarter worth about $81,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Omeros during the 4th quarter valued at about $121,000. BNP Paribas Financial Markets lifted its position in Omeros by 130.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock worth $49,000 after buying an additional 7,016 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in Omeros in the fourth quarter worth approximately $124,000. Finally, Seros Financial LLC bought a new position in Omeros during the fourth quarter valued at approximately $159,000. 48.79% of the stock is currently owned by hedge funds and other institutional investors.

Omeros Stock Up 7.1 %

NASDAQ:OMER opened at $8.42 on Friday. The firm has a market capitalization of $487.94 million, a P/E ratio of -3.65 and a beta of 2.03. Omeros Co. has a 52 week low of $2.61 and a 52 week high of $13.60. The company has a fifty day moving average of $8.80 and a 200 day moving average of $7.15.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the stock. Needham & Company LLC restated a “hold” rating on shares of Omeros in a report on Friday, January 17th. D. Boral Capital reissued a “buy” rating and issued a $36.00 price target on shares of Omeros in a research note on Thursday, February 20th. Finally, StockNews.com raised Omeros from a “sell” rating to a “hold” rating in a research note on Thursday. Three equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Omeros presently has an average rating of “Moderate Buy” and a consensus target price of $22.50.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.